Toni Choueiri, MD, Dana-Farber Cancer Institute
Articles
Final Thoughts on the Management of mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Additional Emerging Therapies for Progressive mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Emerging Agents for Progressive mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Sequencing After Frontline I/O Based Regimen for mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Clinical Trials for Relapsed/Refractory mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Upcoming Combination Trials for mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
I/O Therapy After Progression on I/O for mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Role of TKI After Progression on I/O for mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Review of the COSMIC 021 Study for mRCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
Introduction and Review of CheckMate 9ER for Metastatic RCC
Toni Choueiri, MD, Dana-Farber Cancer Institute;Rana R. McKay, MD, University of California, San Diego;Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center;Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center;Bernard Escudier, MD, Institut Gustave Roussy
October 23rd 2020Read More
